Benza, Raymond L., Langleben, David, Hemnes, Anna R., Noordegraaf, Anton Vonk, Rosenkranz, Stephan, Thenappan, Thenappan ORCID: 0000-0002-6210-0467, Hassoun, Paul M., Preston, Ioana R., Ghio, Stefano, Badagliacca, Roberto, Vizza, Carmine D., Lang, Irene M., Meier, Christian and Gruenig, Ekkehard (2022). Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev., 31 (166). SHEFFIELD: EUROPEAN RESPIRATORY SOC JOURNALS LTD. ISSN 1600-0617

Full text not available from this repository.

Abstract

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Benza, Raymond L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Langleben, DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hemnes, Anna R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Noordegraaf, Anton VonkUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rosenkranz, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thenappan, ThenappanUNSPECIFIEDorcid.org/0000-0002-6210-0467UNSPECIFIED
Hassoun, Paul M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Preston, Ioana R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ghio, StefanoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Badagliacca, RobertoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vizza, Carmine D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lang, Irene M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meier, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gruenig, EkkehardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-695077
DOI: 10.1183/16000617.0061-2022
Journal or Publication Title: Eur. Respir. Rev.
Volume: 31
Number: 166
Date: 2022
Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD
Place of Publication: SHEFFIELD
ISSN: 1600-0617
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
SOLUBLE GUANYLATE-CYCLASE; ENDOTHELIN-RECEPTOR ANTAGONIST; RIGHT HEART; EXERCISE CAPACITY; BOSENTAN TREATMENT; PROGNOSTIC VALUE; SILDENAFIL; PARAMETERS; MANAGEMENT; SURVIVALMultiple languages
Respiratory SystemMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69507

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item